DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Namenda (Memantine Hydrochloride) - Summary



Namenda® Tablets/Oral Solution
(memantine hydrochloride)

NAMENDA™ (memantine hydrochloride) is an orally active NMDA receptor antagonist.

NAMENDA (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

See all Namenda indications & dosage >>


Media Articles Related to Namenda (Memantine)

Positive initial phase 2a study data with ANAVEX 2-73 showing early evidence of improving cognition in patients with Alzheimer's disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Anavex Life Sciences Corp. has announced initial positive cognitive data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's targeting sigma-1 and muscarinic...

New data presented from phase 1b study of investigational Alzheimer's disease treatment Aducanumab (BIIB037)
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Today Biogen has announced new results from a prespecified interim analysis of PRIME, the Phase 1b placebo-controlled study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's...

Novel monoclonal antibodies show promise for Alzheimer's disease treatment
Source: Neurology / Neuroscience News From Medical News Today [2015.07.21]
Parkinson's disease may also be treated with potential therapyScientists at NYU Langone Medical Center's Center for Cognitive Neurology have evidence that monoclonal antibodies they developed may...

One Target, One Treatment? Not for Alzheimer's Disease
Source: Medscape NeurologyHeadlines [2015.07.20]
Promising new therapeutic candidates for Alzheimer's target multiple disease-related proteins and may have benefit in other neurodegenerative diseases.
Medscape Medical News

A Saliva Test for Alzheimer's Disease?
Source: Medscape NeurologyHeadlines [2015.07.20]
Canadian researchers are investigating use of metabolomics to evaluate the cognitive predictive value of saliva samples from persons with normal cognition, mild cognitive impairment, and Alzheimer's disease.
Medscape Medical News

more news >>

Published Studies Related to Namenda (Memantine)

Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. [2014]
analysis of memantine... CONCLUSIONS: New definitions of clinical worsening based on MIDs represent a more

Genotype variant associated with add-on memantine in bipolar II disorder. [2014]
Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist with a mood-stabilizing effect. We investigated whether using valproic acid (VPA) plus add-on memantine to treat bipolar II disorder (BP-II) is more effective than using VPA alone (VPA + Pbo)...

Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. [2014]
and (iv) placebo in delaying clinical progression in AD... CONCLUSION: This large multicenter trial will address the unanswered question of

Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. [2013]
Memantine is a noncompetitive NMDA receptor antagonist...

Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. [2013]
We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia. In a double-blind placebo-controlled clinical trial, 40 patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) who were stabilized on risperidone for a minimum of 8 weeks were randomized to either memantine (20 mg) or placebo in addition to risperidone, 6 mg/d, for eight weeks...

more studies >>

Clinical Trials Related to Namenda (Memantine)

Memantine and Intensive Speech-Language Therapy in Aphasia [Completed]

- Aphasia, the loss or impairment of language caused by brain damage, is one of the most

devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy and drugs. Conventional speech-language therapy in chronic aphasic subjects is of little help and several drugs have been studied with limited success. Therefore other therapeutic strategies are warranted.

- Recent data suggest that drugs (memantine) acting on the brain chemical glutamate may

help the recovery of cognitive deficits, included language, in subjects with vascular dementia. The present study examines the safety profile and efficacy of memantine paired with intensive language therapy in subjects with stroke-related chronic aphasia (more than 1 yr. of evolution).

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury [Recruiting]
The purpose of this study is to determine whether memantine (Namenda) improves memory and attention in patients with mild to moderate traumatic brain injury.

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease [Recruiting]
The primary study hypothesis is that compared with placebo, alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease.

Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy [Not yet recruiting]
People with epilepsy often experience problems with their memories and other thinking skills that get worse over time. The investigators hope to learn more about whether a drug called memantine can help improve or stabilize (keep the same) memory and other thought processes in people with epilepsy by blocking a chemical that is released in the brain during seizures. The investigators also want to see if memantine changes the frequency (how often) people with epilepsy have seizures. Memantine is currently approved by the United States Food and Drug Administration (FDA) for treatment of patients with Alzheimer's disease.

A Study of Memantine Hydrochloride (Namenda�) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders [Recruiting]
The main objective of this study is to evaluate the safety and effectiveness of memantine (Namenda) for cognitive and behavioral impairment in adults ages 18-45 years with autism spectrum disorders (ASD). This is an exploratory, 12-week, pilot study, seeking to determine whether Namenda is efficacious and well tolerated in the treatment of adults with ASD. The study results will be used to generate hypotheses for a larger randomized controlled clinical trial with explicit hypotheses and sufficient statistical power.

more trials >>

Reports of Suspected Namenda (Memantine) Side Effects

Confusional State (7)Dizziness (5)Abnormal Behaviour (5)Tremor (5)Movement Disorder (4)Drug Interaction (4)OFF Label USE (4)Asthenia (4)Thinking Abnormal (3)Balance Disorder (3)more >>

Page last updated: 2015-07-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015